Table 2.
Laboratory diagnoses | No. diagnosed/no. tested | No. HIV co-infecteda | Any CXR abnormality n (%b) | Any opacity n (%b) | Nodules n (%b) | Pleural effusion n (%b) | Cavitation n (%b) | Lymphadenopathy n (%b) |
---|---|---|---|---|---|---|---|---|
HIV infection | 119 / 268 | -- | 79 (66.4) | 48 (40.3) | 16 (13.4) | 14 (11.8) | 5 (4.2) | 11 (9.2) |
Streptococcus pneumoniae | 20 / 267 | 14 (70) | 15 (75) | 11 (55) | 1 (5) | 2 (10) | 1 (5) | -- |
Coxiella burnetii | 13 / 142 | 6 (46.2) | 9 (69.2) | 7 (53.8) | 1 (7.7) | 1 (7.7) | 2 (15.4) | -- |
Leptospira spp. | 13 / 143 | 2 (15.3) | 6 (46.2) | 3 (23.1) | 1 (7.7) | 1 (7.7) | 1 (7.7) | -- |
SFGR | 13 / 142 | 2 (15.3) | 8 (61.5) | 6 (46.2) | 1 (7.7) | 1 (7.7) | 2 (15.4) | |
Cryptococcus neoformans | 13 / 267 | 13 (100) | 9 (69.2) | 3 (23.1) | 4 (30.8) | 2 (15.4) | 1 (7.7) | -- |
Salmonella Typhi | 12 / 267 | 0 (0) | 1 (8.3) | -- | 1 (8.3) | -- | 1 (8.3) | 2 (16.7) |
Kaposi sarcoma | 9 / 120 | 9 (100) | 8 (88.9) | 6 (66.7) | 3 (33.3) | -- | -- | 2 (22.2) |
Mycobacterium tuberculosis | 8 / 267 | 8 (100) | 7 (87.5) | 4 (50) | 1 (12.5) | 3 (37.5) | 1 (12.5) | -- |
Plasmodium spp. | 8 / 266 | 0 (0) | 1 (12.5) | -- | -- | 1 (12.5) | -- | -- |
Brucella spp. | 7 / 143 | 1 (14.3) | 3 (42.9) | 2 (28.6) | 1 (14.3) | 1 (14.3) | -- | 1 (14.3) |
Escherichia coli | 4 / 267 | 3 (75) | 1 (25) | 1 (25) | -- | -- | -- | -- |
Histoplasma capsulatum | 4 / 212 | 3 (75) | 3 (75) | 1 (25) | 2 (50) | -- | -- | 1 (25) |
Staphylococcus aureus | 3 / 267 | 1 (33.3) | 2 (66.7) | 1 (33.3) | 1 (33.3) | -- | -- | -- |
TGR | 2 / 142 | 1 (50) | -- | -- | -- | -- | -- |
Percent (%) based on number HIV-infected diagnosed with condition (co-infection) by total number diagnosed.
Percent (%) based on number with specific abnormality by number of diagnosed with condition.
HIV, human immunodeficiency virus; SFGR, spotted fever group rickettsioses; TGR, typhus group rickettsioses.